Synergism between bioengineered miR‐34a prodrug and doxorubicin in suppressing osteosarcoma cell proliferation and xenograft tumor growth
Mei‐Juan Tu(University of California, Davis), Ai‐Ming Yu(University at Buffalo, State University of New York), Weipeng Wang, Yong Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Aixi Yu(Wuhan University), Qiuxia Chen, Yifeng Yu(Wuhan University), Jingxin Qiu(University of Florida)
Cited by 0
Related Papers
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
RNA therapy: Are we using the right molecules?
|Pharmacology & Therapeutics|2018|172
Laboratory Diagnosis of Four Recent Sporadic Cases of Community-acquired SARS, Guangdong Province, China
|Emerging infectious diseases|2004|137